If you have been reading about anti-doping category and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
=== Development and marketing === Prior to the development of remifentanil, most short-acting hypnotics and amnestics faced issues with prolonged use, where accumulation would result in unfavorable lingering effects during post-operative recovery. Remifentanil was designed to serve as a strong anesthetic with an ultra-short and predictable duration that would not have accumulation issues. Remifentanil was patented by Glaxo Wellcome Inc. and was FDA approved on July 12, 1996. Its patent ended on the 10th of September 2017.
The study of mechanical or "formal" reasoning began with philosophers and mathematicians in antiquity. The study of logic led directly to Alan Turing's theory of computation, which suggested that a machine, by shuffling symbols as simple as "0" and "1", could simulate any conceivable form of mathematical reasoning. This, along with concurrent discoveries in cybernetics, information theory and neurobiology, led researchers to consider the possibility of building an "electronic brain". They developed several areas of research that would become part of AI, such as McCulloch and Pitts design for "artificial neurons" in 1943, and Turing's influential 1950 paper 'Computing Machinery and Intelligence', which introduced the Turing test and showed that "machine intelligence" was plausible. The field of AI research was founded at a workshop at Dartmouth College in 1956. The first AI program, Logic Theorist, was presented at the workshop, created by future Turing Award winner Allen Newell and future Nobel Laureate Herbert A. Simon, in collaboration with J. C. Shaw. Many of the workshop attendees became the leaders of AI research in the 1960s. They and their students produced programs that the press described as "astonishing": computers were learning checkers strategies, solving word problems in algebra, proving logical theorems and speaking English. Artificial intelligence laboratories were set up at a number of British and U.S. universities in the latter 1950s and early 1960s.
== General mammalian research == Migliaro Petroni et al. (2026) describe tracks of a small-bodied, fast-moving mammal from the Upper Cretaceous (Maastrichtian) strata of the Yacoraite Formation (Argentina), assigned to the ichnotaxon Brasilichnium cf. saltatorium and extending known stratigraphic distribution of the ichnogenus Brasilichnium. A new, diverse assemblage of teeth of Paleocene (Torrejonian) mammals is reported from the Tullock Member of the Fort Union Formation (Montana, United States) by Hovatter & Wilson Mantilla (2026). Evidence indicating that carbon isotope excursions and probable warming events during the Danian were associated with strong pulses of turnover of mammalian assemblages is reported from the study of the fossil record from the San Juan Basin (New Mexico, United States) and other basins in the Rocky Mountain Region is presented by Secord et al. (2026). Evidence from the study of teeth of Paleocene placentals from the Nanxiong, Qianshan and Chijiang basins (China), indicating that the studied mammals achieved high dental topographic variability during the first 10 million years of the Cenozoic and that the variability of their dental traits paralleled global and regional environmental changes, is presented by Tseng, Li & Ting (2026), who argue that living placental lineages might originate from phenotypically variable and functionally flexible ancestors such as the mammals from the studied assemblages from paleotropical Asia.
Sources: en.wikipedia.org
According to the fluid mosaic model of S. J. Singer and G. L. Nicolson (1972), which replaced the earlier model of Davson and Danielli, biological membranes can be considered as a two-dimensional liquid in which lipid and protein molecules diffuse more or less easily. Although the lipid bilayers that form the basis of the membranes do indeed form two-dimensional liquids by themselves, the plasma membrane also contains a large quantity of proteins, which provide more structure. Examples of such structures are protein-protein complexes, pickets and fences formed by the actin-based cytoskeleton, and potentially lipid rafts.
Caesium-135 is a mildly radioactive isotope of caesium with a half-life of 1.33 million years. It decays via emission of a low-energy beta particle into the stable isotope barium-135. Caesium-135 is one of the seven long-lived fission products and the only alkaline one. In most types of nuclear reprocessing, it stays with the medium-lived fission products (including 137Cs which can only be separated from 135Cs via isotope separation) rather than with other long-lived fission products. As an exception, molten salt reactors create 135Cs as a completely separate stream outside the fuel (after the decay of bubble-separated 135Xe). The low decay energy, lack of gamma radiation, and long half-life of 135Cs make this isotope much less hazardous than 137Cs or 134Cs. Its precursor 135Xe has a high fission product yield (e.g., 6.3333% for 235U and thermal neutrons) but also has the highest known thermal neutron capture cross section of any nuclide. Because of this, much of the 135Xe produced in current thermal reactors (as much as >90% at steady-state full power) will be converted to practically stable 136Xe before it can decay to 135Cs despite the relatively short half-life of 135Xe. Little or no 135Xe will be destroyed by neutron capture after a reactor shutdown, or in a molten salt reactor that continuously removes xenon from its fuel, a fast neutron reactor, or a nuclear weapon.
== Mechanism of action == Upon binding to its ligand GLP-1, the GLP-1 receptor activates intracellular signaling pathways that regulate insulin secretion, glucose metabolism, and satiety. In pancreatic beta cells, GLP-1 receptor activation enhances glucose-stimulated insulin secretion. This occurs through the activation of adenylyl cyclase, leading to increased intracellular levels of cyclic AMP (cAMP). The rise in cAMP activates protein kinase A (PKA), which promotes insulin exocytosis and enhances beta cell survival and proliferation. GLP-1 receptor signaling in pancreatic alpha cells reduces glucagon secretion, further contributing to glucose lowering. Activation of GLP-1 receptor delays the rate at which the stomach empties, leading to increased satiety and feeling of fullness. Activation of the GLP-1 receptor in the brain promotes feelings of satiety.
Khrulyov also said that the first battalion passed the Roki Tunnel at 01:40 AM on 8 August and the second battalion had just entered the tunnel. The battalions reached the Gufta bridge at 04:40 AM on 8 August, when the Georgians had just approached from the other side. In 2012, one Russian soldier wrote in his memoirs that his military unit received the order to deploy to the Georgian border on 5 August 2008 and early in the morning of August 5th, they had already left the base.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.